Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking Mounjaro a few hours early on a given week is generally considered acceptable and will not reset your dose schedule or meaningfully change how the medicine works. Mounjaro (tirzepatide) has a half-life of approximately five days, so a shift of a few hours sits well within the natural variation that clinical guidance accounts for. That said, Mounjaro is a prescription-only medicine, and how you manage your schedule should always be discussed with your prescriber, who can account for your full clinical picture. The NHS tirzepatide information page confirms the weekly injection schedule and directs patients to their prescriber or the Patient Information Leaflet for any questions about timing.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Many people assume that injecting Mounjaro even slightly outside the exact weekly window invalidates the dose or forces a restart. That is not how this medicine works. Tirzepatide is absorbed subcutaneously and builds to a stable concentration over several weeks of treatment; its long half-life of roughly five days means the body's exposure changes gradually rather than spiking and crashing the way a short-acting drug would. A shift of two, three or four hours in either direction sits comfortably within the pharmacokinetic profile the medicine was designed around. This is a question our prescribers hear most weeks, particularly from patients travelling or managing a busy schedule, and the reassurance is consistent: a small timing adjustment does not undo a dose or require any corrective action.
That said, 'a few hours' and 'a full day or more' are genuinely different situations. If you are considering a larger shift, pages like our guide to taking Mounjaro a day early explore that territory specifically, because the considerations change as the interval shortens significantly. For now, a few hours remains well within normal tolerance.
The once-weekly schedule is set not for administrative convenience but because the medicine's pharmacology demands it. Too frequent, and steady-state levels climb unpredictably; the weekly interval keeps absorption and effect consistent across the treatment period. Injecting a few hours early does not shorten that interval enough to create a clinically relevant problem. What it does mean is that your next dose date moves accordingly: if you inject on Monday evening instead of Tuesday morning, your following injection is due the following Monday evening, not Tuesday. The schedule shifts, it does not compress.
For anyone uncertain about the full dosing picture, the BNF entry for tirzepatide sets out the professional prescribing framework, and your own Patient Information Leaflet provides patient-level detail. Both are the definitive sources; no content page replaces them. If you are newly starting treatment or weighing up which approach fits your lifestyle, our Mounjaro overview gives a fuller picture of the medicine as a whole.
A few hours of flexibility is low-stakes. Some situations are not. If you are repeatedly adjusting your injection day because your schedule makes Tuesdays (or whichever day you chose) unworkable, it is worth formally changing your injection day with your prescriber's support rather than drifting gradually through the week. Similarly, if an early injection is happening because of a planned procedure or surgery, your clinical team needs to know you are taking tirzepatide in any case, NHS England's guidance on weight-management injections is clear that anaesthetic teams should be informed before any surgical procedure.
Certain health conditions also affect how tirzepatide interacts with your digestive system, and timing can become more relevant in those contexts. If you have any gastrointestinal condition, including inflammatory bowel disease, our page on Mounjaro and ulcerative colitis covers what's known. Likewise, if you take other medicines alongside Mounjaro, particularly ones with narrow timing windows, a prescriber should review the combination, our guide to painkillers and Mounjaro is one example of where timing and drug interactions overlap.
Questions about injection timing tend to emerge once someone is settled into treatment, which is a good sign. It means the medicine is part of their routine rather than an ordeal. Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition, and treatment continues to be reviewed clinically throughout. Staying on track with your weekly schedule, roughly, is part of getting the most from it. If you are still exploring whether Mounjaro suits your circumstances, our BMI eligibility page for Mounjaro is a useful starting point.
At nume, every repeat order is reviewed by a real prescriber before it is dispensed, not auto-renewed. If your schedule or circumstances have changed, that review is the natural moment to flag it. Our weight-loss treatment overview sets out the broader options, and the cost context for private Mounjaro treatment is covered honestly on our Mounjaro cost page. If you have specific questions before starting, the FAQs page covers the most common ones. When you are ready to take the next step, check your eligibility with a free consultation, a named prescriber reviews every submission the same day it arrives.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.